Compare AIXI & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIXI | NEUP |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 10.3M |
| IPO Year | 2023 | N/A |
| Metric | AIXI | NEUP |
|---|---|---|
| Price | $0.65 | $4.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 189.8K | 135.2K |
| Earning Date | 12-26-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,314,315.00 | $15,649,448.00 |
| Revenue This Year | $26.84 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.84 | N/A |
| 52 Week Low | $0.60 | $2.90 |
| 52 Week High | $6.65 | $21.40 |
| Indicator | AIXI | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 36.75 | 40.75 |
| Support Level | $0.64 | $4.10 |
| Resistance Level | $0.71 | $4.60 |
| Average True Range (ATR) | 0.08 | 0.28 |
| MACD | 0.01 | 0.25 |
| Stochastic Oscillator | 19.98 | 48.89 |
XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.